Enliven Therapeutics CFO Disposes of 6,018 Shares Under Pre-Arranged Trading Plan
Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported a significant insider transaction as Chief Financial Officer Benjamin Hohl executed the sale of 6,018 shares of the company's common stock on June 17, 2026. The transaction, valued at $263,577, was conducted through a Rule 10b5-1 trading plan adopted earlier in the year. This sale follows a period …